4D Molecular Therapeutics | LinkedIn (original) (raw)

Biotechnology Research

Emeryville, California 16,473 followers

Powering the Future of Genetic Medicines

About us

4DMT is a clinical stage biopharma company inventing and developing innovative products to unlock the full potential of genetic medicine to treat large market and rare diseases. Our vector discovery platform Therapeutic Vector Evolution harnesses the power of directed evolution, a Nobel Prize-winning technology, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors with improved therapeutic profiles compared to wild-type vectors. Our product design, development and manufacturing engine empowers us to efficiently create our valuable and diverse product pipeline. This combination of bold innovation and relentless execution gives 4DMT the capability to revolutionize genetic medicines and to strive for potential curative therapies. We have built a deep portfolio of genetic medicine product candidates, with five product candidates in clinical trials for seven patient populations. We are taking genetic medicine to new heights and into new disease areas to overcome challenges not addressed by existing medicines. This incredible challenge drives our relentless and talented team. Our people are the essence of our inspiring, innovative and collaborative environment that encourages individual contributions and provides opportunities for career development. We seek the best in the industry who identify with our mission and our bold and innovative results-driven approach. Our 4 Guiding Principles drive the way we work together: - Dare to Cure - Break Boundaries - Beyond Yourself - Prepare & Execute Relentlessly Join us in creating the future of genetic medicine.

Industry

Biotechnology Research

Company size

51-200 employees

Headquarters

Emeryville, California

Type

Public Company

Founded

2013

Specialties

Gene Therapy, Adeno-Associated Virus, Biotechnology, Rare Diseases, Clinical, Lab, Clinical Trials, and Science

Locations

Employees at 4D Molecular Therapeutics

Updates

In the recent instalment of Scrip Asks our CEO, David Kirn, MD, shared his predictions for the #biopharma industry in 2025. As we move into the new year, we foresee a year of impactful advancements, with stronger collaborations in clinical trials, exciting innovations in #ophthalmology treatments and a renewed focus on developing leadership to shape the future of #biopharma and improve patient care. Dive into the article to get the full insights from David: https://lnkd.in/gg_sNJhj Citeline #ScripAsks2025
From the 4DMT team, happy 40th birthday Emily Kramer-Golinkoff! For individuals living with #cysticfibrosis like Emily, this is an amazing milestone birthday to achieve and reminds us of the incredible work that Emily's Entourage does for the CF community. We’re proud to support and help advocate for the remaining 10% of people with CF who do not benefit from existing therapies and need new life-saving solutions.
🎂 IT’S OFFICIALLY HERE—HAPPY 40TH, EMILY! 🎂 When Emily was born in 1985, life expectancy for someone with #cysticfibrosis was just 25 years. Today, she is turning 40 🤯. Her story is proof of what happens when science, grit, love, and determination collide. Today, we’re celebrating Emily and we’re pushing HARD to keep the candles and milestones coming for the final 10% of the #CF community. There could be no greater gift in the world for our birthday girl, Emily, than that! 👉 Join the celebration—give $40 for Emily’s 40th >>> https://lnkd.in/gSdtSb5E. . .#40for40 #AgainstAllOdds #EmilyTurns40 #CureCF #CFAwareness #CFirl
This morning, we announced big news that sets the stage for a new chapter for 4DMT. First, we shared positive interim #data from Part 1 of the SPECTRA #ClinicalTrial evaluating 4D-150 in #DiabeticMacularEdema (DME) and FDA alignment on a single Phase 3 clinical trial being acceptable for the basis of a BLA submission backed by review of data from the SPECTRA and PRISM (wet AMD) clinical trials to date and global Phase 3 development program for wet AMD. Per FDA feedback, we may directly proceed Phase 3. Building on the momentum of the DME announcement, we also issued a press release strategically focusing our pipeline, with 4D-150 and 4D-710 as our lead candidates, which have the strongest clinical proof of concept. This pipeline prioritization extends our cash runway into 2028, which is beyond the topline readouts for 4FRONT-1 and 4FRONT-2, our Phase 3 studies in wet AMD. See the full details of the 4D-150 DME data here: https://lnkd.in/ettJywZ2Learn more about our strategic pipeline prioritization here: https://lnkd.in/e6jafVvj
16,473 followers
1mo Edited
At 4DMT, we’re inspired by our guiding principles to focus awareness on social equity and create positive change not only within 4DMT, but in our community at large. Last month, our team worked with the Alameda County Community Food Bank for an unforgettable volunteer day. We learned about their incredible operations distributing food across 14 cities, actively participated in tasks such as onion sorting and crate building, and even appeared in the Food Bank’s video showcasing their freshly harvested kale! Thank you to our volunteers for making a difference in our community #VolunteerDay #BeyondYourself
Our Chief Financial & Business Officer, Uneek Mehra, and Chief Development Officer, Dhaval B. Desai, PharmD, shared insights on 4DMT’s clinical programs and explored the advancements shaping the future of #GeneticMedicines at the Jefferies London Healthcare Conference last week. Our team enjoyed connecting with leaders and innovators across the global biotech and investment communities. Thank you to everyone who joined us for meaningful conversations.#JefferiesHealthcare

Join now to see what you are missing

Join now

4D Molecular Therapeutics | LinkedIn (original) (raw)

Biotechnology Research

Emeryville, California 16,473 followers

Powering the Future of Genetic Medicines

About us

Locations

Employees at 4D Molecular Therapeutics

Updates

Join now to see what you are missing

Similar pages

Browse jobs

Funding